Graft Versus Leukemia: Current Status and Future Perspectives

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01801 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434054 Graft Versus Leukemia: Current Status and Future Perspectives Aideen T. O'Neill, MBBS, MRCP, FRCPath1xAideen T. O'NeillSearch for articles by this author and Ronjon Chakraverty, MBChB, MRCP, FRCPath, PhD1xRonjon ChakravertySearch for articles by this author Show More 1MRC Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom https://doi.org/10.1200/JCO.20.01801 First Page Full Text PDF Figures and Tables Supplements © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveRelapse of hematologic malignancy is the major reason for treatment failure after allogeneic stem cell transplantation.Knowledge GeneratedGraft-versus-leukemia (GVL) responses are critical to prevent relapse but may fail as a result of tumor immune evasion, for example through antigen loss or T cell dysfunction. In silico pipelines for the discovery of tumor-expressed antigens and novel therapies that target immune evasion mechanisms (small molecule, biological, immune cell transfer) are potential strategies to sustain or reimpose GVL.RelevanceA key challenge will be how experimental therapies to enhance GVL can progress from first-in-human trials to prospective, controlled trials that evaluate efficacy and lead to regulatory approval.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTGraft Versus Leukemia: Current Status and Future PerspectivesThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Ronjon ChakravertyConsulting or Advisory Role: NovartisNo other potential conflicts of interest were reported.